Oliver Von Richter
Holzkirchen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: April 28, 2025
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies.
Journal: Expert opinion on biological therapy
Published: November 15, 2024
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: September 06, 2024
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: July 02, 2024
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile.
Journal: Frontiers in immunology
Published: April 08, 2024
'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Journal: Advances in therapy
Published: December 18, 2023
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial.
Journal: Expert opinion on biological therapy
Published: December 04, 2023
First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: November 16, 2022
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar.
Journal: Expert opinion on biological therapy
Published: August 30, 2022
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: January 16, 2020
Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.
Journal: Expert opinion on biological therapy
Published: July 10, 2019
Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar.
Journal: Expert opinion on biological therapy
Published: April 20, 2019
Last Updated: 09/26/2026